Early molecular and behavioral response to lipopolysaccharide in the WAG/Rij rat model of absence epilepsy and depressive-like behavior, involves interplay between AMPK, AKT/mTOR pathways and neuroinflammatory cytokine release

Brain, Behavior, and Immunity

Volumn 42, Issue , 2014, Pages 157-168

  Russo, Emilio ^a   Andreozzi, Francesco ^a   Iuliano, Rodolfo ^a   Dattilo, Vincenzo ^a   Procopio, Teresa ^a   Fiume, Giuseppe ^a   Mimmi, Selena ^a   Perrotti, Nicola ^a   Citraro, Rita ^a   Sesti, Giorgio ^a   Constanti, Andrew ^b   De Sarro, Giovambattista ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Absence epilepsy; AKT; AMPK; Cytokines; Epileptogenesis; Lipopolysaccharide (LPS); MTOR; Neuroinflammation; NF B; Rapamycin; WAG Rij rats

Indexed keywords

ADENYLATE KINASE; BETA ACTIN; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PROTEIN KINASE B; RAPAMYCIN; RNA 18S; S6 KINASE; TUMOR NECROSIS FACTOR ALPHA; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN CORTEX; CONTROLLED STUDY; CYTOKINE RELEASE; DEPRESSION; ELECTROENCEPHALOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; EPILEPSY; FORCED SWIM TEST; HIPPOCAMPUS; MALE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; THALAMUS; WESTERN BLOTTING; WISTAR ALBINO GLAXO RAT; ABSENCE; ANIMAL; ANIMAL BEHAVIOR; BRAIN; DISEASE MODEL; DRUG EFFECTS; ELECTROENCEPHALOGRAPHY; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; WISTAR RAT;

ADENYLATE KINASE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CYTOKINES; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; EPILEPSY, ABSENCE; LIPOPOLYSACCHARIDES; MALE; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84908609402     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2014.06.016     Document Type: Article

References (84)

1. Abelaira H.M., Reus G.Z., Neotti M.V., Quevedo J. The role of mTOR in depression and antidepressant responses. Life Sci. 2014, 101:10-14.
2. Akin D., Ravizza T., Maroso M., Carcak N., Eryigit T., Vanzulli I., Aker R.G., Vezzani A., Onat F.Y. IL-1beta is induced in reactive astrocytes in the somatosensory cortex of rats with genetic absence epilepsy at the onset of spike-and-wave discharges, and contributes to their occurrence. Neurobiol. Dis. 2011, 44:259-269.
3. Aronica E., Crino P.B. Inflammation in epilepsy: clinical observations. Epilepsia 2011, 52(Suppl. 3):26-32.
4. Avanzini G., Manganotti P., Meletti S., Moshe S.L., Panzica F., Wolf P., Capovilla G. The system epilepsies: a pathophysiological hypothesis. Epilepsia 2012, 53:771-778.
5. Ayasolla K.R., Singh A.K., Singh I. 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) attenuates the expression of LPS- and Abeta peptide-induced inflammatory mediators in astroglia. J. Neuroinflamm. 2005, 2:21.
6. Blumenfeld H., Klein J.P., Schridde U., Vestal M., Rice T., Khera D.S., Bashyal C., Giblin K., Paul-Laughinghouse C., Wang F., Phadke A., Mission J., Agarwal R.K., Englot D.J., Motelow J., Nersesyan H., Waxman S.G., Levin A.R. Early treatment suppresses the development of spike-wave epilepsy in a rat model. Epilepsia 2008, 49:400-409.
7. Cambiaghi M., Cursi M., Magri L., Castoldi V., Comi G., Minicucci F., Galli R., Leocani L. Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex. Neuropharmacology 2013, 67:1-7.
8. Cao M., Tan X., Jin W., Zheng H., Xu W., Rui Y., Li L., Cao J., Wu X., Cui G., Ke K., Gao Y. Upregulation of Ras homolog enriched in the brain (Rheb) in lipopolysaccharide-induced neuroinflammation. Neurochem. Int. 2013, 62:406-417.
9. Chi H. Regulation and function of mTOR signalling in T cell fate decisions. Nat. Rev. Immunol. 2012, 12:325-338.
10. Chong Z.Z., Shang Y.C., Wang S., Maiese K. A critical kinase cascade in neurological disorders: PI 3-K, Akt, and mTOR. Future Neurol. 2012, 7:733-748.
11. Citraro R., Russo E., Di Paola E.D., Ibbadu G.F., Gratteri S., Marra R., De Sarro G. Effects of some neurosteroids injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy. Neuropharmacology 2006, 50:1059-1071.
12. Citraro R., Russo E., Gratteri S., Di Paola E.D., Ibbadu G.F., Curinga C., Gitto R., Chimirri A., Donato G., De Sarro G. Effects of non-competitive AMPA receptor antagonists injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy. Neuropharmacology 2006, 51:1058-1067.
13. Citraro R., Russo E., Ngomba R.T., Nicoletti F., Scicchitano F., Whalley B.J., Calignano A., De Sarro G. CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations. Epilepsy Res. 2013, 106:74-82.
14. Citraro R., Russo E., Scicchitano F., van Rijn C.M., Cosco D., Avagliano C., Russo R., D'Agostino G., Petrosino S., Guida F., Gatta L., van Luijtelaar G., Maione S., Di Marzo V., Calignano A., De Sarro G. Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-alpha receptor activation in a genetic model of absence epilepsy. Neuropharmacology 2013, 69:115-126.
15. Citraro R., Scicchitano F., De Fazio S., Raggio R., Mainardi P., Perucca E., De Sarro G., Russo E. Preclinical activity profile of alpha-lactalbumin, a whey protein rich in tryptophan, in rodent models of seizures and epilepsy. Epilepsy Res. 2011, 95:60-69.
16. Curatolo P., Moavero R. MTOR inhibitors as a new therapeutic option for epilepsy. Expert Rev. Neurother. 2013, 13:627-638.
17. D'Ambrosio R., Eastman C.L., Fattore C., Perucca E. Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation. Expert Rev. Neurother. 2013, 13:615-625.
18. Dello Russo C., Lisi L., Feinstein D.L., Navarra P. MTOR kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis. Glia 2013, 61:301-311.
19. Devinsky O., Vezzani A., Najjar S., De Lanerolle N.C., Rogawski M.A. Glia and epilepsy: excitability and inflammation. Trends Neurosci. 2013, 36:174-184.
20. Duman R.S., Li N., Liu R.J., Duric V., Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012, 62:35-41.
21. Dunn A.J., Swiergiel A.H. Effects of interleukin-1 and endotoxin in the forced swim and tail suspension tests in mice. Pharmacol. Biochem. Behav. 2005, 81:688-693.
22. Fiume G., Vecchio E., De Laurentiis A., Trimboli F., Palmieri C., Pisano A., Falcone C., Pontoriero M., Rossi A., Scialdone A., Fasanella Masci F., Scala G., Quinto I. Human immunodeficiency virus-1 Tat activates NF-kappaB via physical interaction with IkappaB-alpha and p65. Nucleic Acids Res. 2012, 40:3548-3562.
23. Galanopoulou A.S., Gorter J.A., Cepeda C. Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target. Epilepsia 2012, 53:1119-1130.
24. Galic M.A., Riazi K., Pittman Q.J. Cytokines and brain excitability. Front. Neuroendocrinol. 2012, 33:116-125.
25. Giri S., Nath N., Smith B., Viollet B., Singh A.K., Singh I. 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J. Neurosci. 2004, 24:479-487.
26. Gwinn D.M., Shackelford D.B., Egan D.F., Mihaylova M.M., Mery A., Vasquez D.S., Turk B.E., Shaw R.J. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 2008, 30:214-226.
27. Hurley L.L., Tizabi Y. Neuroinflammation, neurodegeneration, and depression. Neurotox. Res. 2013, 23:131-144.
28. Jernigan C.S., Goswami D.B., Austin M.C., Iyo A.H., Chandran A., Stockmeier C.A., Karolewicz B. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:1774-1779.
29. Kaster M.P., Gadotti V.M., Calixto J.B., Santos A.R., Rodrigues A.L. Depressive-like behavior induced by tumor necrosis factor-alpha in mice. Neuropharmacology 2012, 62:419-426.
30. Kellom M., Basselin M., Keleshian V.L., Chen M., Rapoport S.I., Rao J.S. Dose-dependent changes in neuroinflammatory and arachidonic acid cascade markers with synaptic marker loss in rat lipopolysaccharide infusion model of neuroinflammation. BMC Neurosci. 2012, 13:50.
31. Kovacs Z., Czurko A., Kekesi K.A., Juhasz G. Intracerebroventricularly administered lipopolysaccharide enhances spike-wave discharges in freely moving WAG/Rij rats. Brain Res. Bull. 2011, 85:410-416.
32. Kovacs Z., Kekesi K.A., Szilagyi N., Abraham I., Szekacs D., Kiraly N., Papp E., Csaszar I., Szego E., Barabas K., Peterfy H., Erdei A., Bartfai T., Juhasz G. Facilitation of spike-wave discharge activity by lipopolysaccharides in Wistar Albino Glaxo/Rijswijk rats. Neuroscience 2006, 140:731-742.
33. Labuzek K., Liber S., Gabryel B., Okopien B. Metformin has adenosine-monophosphate activated protein kinase (AMPK)-independent effects on LPS-stimulated rat primary microglial cultures. Pharmacol. Rep. 2010, 62:827-848.
34. Lang U.E., Borgwardt S. Molecular mechanisms of depression: perspectives on new treatment strategies. Cell. Physiol. Biochem. 2013, 31:761-777.
35. Lawson M.A., McCusker R.H., Kelley K.W. Interleukin-1 beta converting enzyme is necessary for development of depression-like behavior following intracerebroventricular administration of lipopolysaccharide to mice. J. Neuroinflamm. 2013, 10:54.
36. Lee J.Y., Jeon B.T., Shin H.J., Lee D.H., Han J.Y., Kim H.J., Kang S.S., Cho G.J., Choi W.S., Roh G.S. Temporal expression of AMP-activated protein kinase activation during the kainic acid-induced hippocampal cell death. J. Neural Transm. 2009, 116:33-40.
37. Lee P.S., Wilhelmson A.S., Hubner A.P., Reynolds S.B., Gallacchi D.A., Chiou T.T., Kwiatkowski D.J. MTORC1-S6K activation by endotoxin contributes to cytokine up-regulation and early lethality in animals. PLoS ONE 2010, 5:e14399.
38. Lehnardt S., Massillon L., Follett P., Jensen F.E., Ratan R., Rosenberg P.A., Volpe J.J., Vartanian T. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8514-8519.
39. Leibrock C., Ackermann T.F., Hierlmeier M., Lang F., Borgwardt S., Lang U.E. Akt2 deficiency is associated with anxiety and depressive behavior in mice. Cell. Physiol. Biochem. 2013, 32:766-777.
40. Lopes M.W., Soares F.M., de Mello N., Nunes J.C., de Cordova F.M., Walz R., Leal R.B. Time-dependent modulation of mitogen activated protein kinases and AKT in rat hippocampus and cortex in the pilocarpine model of epilepsy. Neurochem. Res. 2012, 37:1868-1878.
41. Loscher, W., 2012. Strategies for antiepileptogenesis: antiepileptic drugs versus novel approaches evaluated in post-status epilepticus models of temporal lobe epilepsy. In: Noebels, J.L., Avoli, M., Rogawski, M.A., Olsen, R.W., Delgado-Escueta, A.V. (Eds.), Jasper's Basic Mechanisms of the Epilepsies, Bethesda (MD).
42. Lu Y., Wang L., He M., Huang W., Li H., Wang Y., Kong J., Qi S., Ouyang J., Qiu X. Nix protein positively regulates NF-kappaB activation in gliomas. PLoS ONE 2012, 7:e44559.
43. Luijtelaar G., Lyashenko S., Vastyanov R., Verbeek G., Oleinik A., Rijn C., Volokhova G., Shandra A., Coenen A., Godlevsky L. Cytokines and absence seizures in a genetic rat model. Neurophysiology 2012, 43:478-486.
44. Macias M., Blazejczyk M., Kazmierska P., Caban B., Skalecka A., Tarkowski B., Rodo A., Konopacki J., Jaworski J. Spatiotemporal characterization of mTOR kinase activity following kainic acid induced status epilepticus and analysis of rat brain response to chronic rapamycin treatment. PLoS ONE 2013, 8:e64455.
45. Maiese K., Chong Z.Z., Shang Y.C., Wang S. MTOR: on target for novel therapeutic strategies in the nervous system. Trends Mol. Med. 2013, 19:51-60.
46. Manning J.P., Richards D.A., Leresche N., Crunelli V., Bowery N.G. Cortical-area specific block of genetically determined absence seizures by ethosuximide. Neuroscience 2004, 123:5-9.
47. Marchi N., Granata T., Janigro D. Inflammatory pathways of seizure disorders. Trends Neurosci. 2014, 37:55-65.
48. Muller N. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr. Opin. Investig. Drugs 2010, 11:31-42.
49. Nagai Y., Akashi S., Nagafuku M., Ogata M., Iwakura Y., Akira S., Kitamura T., Kosugi A., Kimoto M., Miyake K. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat. Immunol. 2002, 3:667-672.
50. Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nat. Neurosci. 2010, 13:1161-1169.
51. Paduano F., Dattilo V., Narciso D., Bilotta A., Gaudio E., Menniti M., Agosti V., Palmieri C., Perrotti N., Fusco A., Trapasso F., Iuliano R. Protein tyrosine phosphatase PTPRJ is negatively regulated by microRNA-328. FEBS J. 2013, 280:401-412.
52. Peinnequin A., Mouret C., Birot O., Alonso A., Mathieu J., Clarencon D., Agay D., Chancerelle Y., Multon E. Rat pro-inflammatory cytokine and cytokine related mRNA quantification by real-time polymerase chain reaction using SYBR green. BMC Immunol. 2004, 5:3.
53. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
54. Ravizza T., Balosso S., Vezzani A. Inflammation and prevention of epileptogenesis. Neurosci. Lett. 2011, 497:223-230.
55. Rimoli M.G., Russo E., Cataldi M., Citraro R., Ambrosino P., Melisi D., Curcio A., De Lucia S., Patrignani P., De Sarro G., Abignente E. T-type channel blocking properties and antiabsence activity of two imidazo[1,2-b]pyridazine derivatives structurally related to indomethacin. Neuropharmacology 2009, 56:637-646.
56. Rosenblat J.D., Cha D.S., Mansur R.B., McIntyre R.S. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 53C:23-34.
57. Russo E., Citraro R., Constanti A., De Sarro G. The mTOR signaling pathway in the brain: focus on epilepsy and epileptogenesis. Mol. Neurobiol. 2012, 46:662-681.
58. Russo E., Citraro R., Davoli A., Gallelli L., Di Paola E.D., De Sarro G. Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology 2013, 64:371-379.
59. Russo E., Citraro R., Davoli A., Gallelli L., Donato Di Paola E., De Sarro G. Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology 2013, 64:371-379.
60. Russo E., Citraro R., De Fazio S., Marra R., Gitto R., Chimirri A., De Sarro G., Di Paola E.D. Enhancement of anti-absence effects of ethosuximide by low doses of a noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist in a genetic animal model of absence epilepsy. Epilepsy Behav. 2008, 13:295-299.
61. Russo E., Citraro R., Donato G., Camastra C., Iuliano R., Cuzzocrea S., Constanti A., De Sarro G. MTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy. Neuropharmacology 2013, 69:25-36.
62. Russo E., Citraro R., Scicchitano F., De Fazio S., Perrotta I., Di Paola E.D., Constanti A., De Sarro G. Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. Epilepsia 2011, 52:1341-1350.
63. Russo E., Citraro R., Scicchitano F., Urzino A., Marra R., Rispoli V., De Sarro G. Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity. Behav. Brain Res. 2011, 225:373-376.
64. Russo E., Follesa P., Citraro R., Camastra C., Donato A., Isola D., Constanti A., De Sarro G., Donato G. The mTOR signaling pathway and neuronal stem/progenitor cell proliferation in the hippocampus are altered during the development of absence epilepsy in a genetic animal model. Neurol. Sci. 2014, in press.
65. Russo E., Scicchitano F., Citraro R., Aiello R., Camastra C., Mainardi P., Chimirri S., Perucca E., Donato G., De Sarro G. Protective activity of alpha-lactoalbumin (ALAC), a whey protein rich in tryptophan, in rodent models of epileptogenesis. Neuroscience 2012, 226:282-288.
66. Saponaro C., Cianciulli A., Calvello R., Dragone T., Iacobazzi F., Panaro M.A. The PI3K/Akt pathway is required for LPS activation of microglial cells. Immunopharmacol. Immunotoxicol. 2012, 34:858-865.
67. Sarkisova K., van Luijtelaar G. The WAG/Rij strain: a genetic animal model of absence epilepsy with comorbidity of depression [corrected]. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:854-876.
68. Sitnikova E., van Luijtelaar G. Cortical control of generalized absence seizures: effect of lidocaine applied to the somatosensory cortex in WAG/Rij rats. Brain Res. 2004, 1012:127-137.
69. van Luijtelaar G., Sitnikova E. Global and focal aspects of absence epilepsy: the contribution of genetic models. Neurosci. Biobehav. Rev. 2006, 30:983-1003.
70. van Vliet E.A., Forte G., Holtman L., den Burger J.C., Sinjewel A., de Vries H.E., Aronica E., Gorter J.A. Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation. Epilepsia 2012, 53:1254-1263.
71. Vezzani A. Before epilepsy unfolds: finding the epileptogenesis switch. Nat. Med. 2012, 18:1626-1627.
72. Vezzani A., Balosso S., Maroso M., Zardoni D., Noe F., Ravizza T. ICE/caspase 1 inhibitors and IL-1beta receptor antagonists as potential therapeutics in epilepsy. Curr. Opin. Investig. Drugs 2010, 11:43-50.
73. Vezzani A., Friedman A., Dingledine R.J. The role of inflammation in epileptogenesis. Neuropharmacology 2013, 69:16-24.
74. Vezzani A., Maroso M., Balosso S., Sanchez M.A., Bartfai T. IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain Behav. Immun. 2011, 25:1281-1289.
75. Vitagliano L., Fiume G., Scognamiglio P.L., Doti N., Cannavo R., Puca A., Pedone C., Scala G., Quinto I., Marasco D. Structural and functional insights into IkappaB-alpha/HIV-1 Tat interaction. Biochimie 2011, 93:1592-1600.
76. Walker F.R. A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression?. Neuropharmacology 2013, 67:304-317.
77. Wang L., Harris T.E., Roth R.A., Lawrence J.C. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J. Biol. Chem. 2007, 282:20036-20044.
78. Wang S.J., Bo Q.Y., Zhao X.H., Yang X., Chi Z.F., Liu X.W. Resveratrol pre-treatment reduces early inflammatory responses induced by status epilepticus via mTOR signaling. Brain Res. 2013, 1492:122-129.
79. Wong M. A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials. Expert Rev. Neurother. 2013, 13:657-669.
80. Xu S.X., Zhou Z.Q., Li X.M., Ji M.H., Zhang G.F., Yang J.J. The activation of adenosine monophosphate-activated protein kinase in rat hippocampus contributes to the rapid antidepressant effect of ketamine. Behav. Brain Res. 2013, 253:305-309.
81. Yang C., Shen J., Hong T., Hu T.T., Li Z.J., Zhang H.T., Zhang Y.J., Zhou Z.Q., Yang J.J. Effects of ketamine on lipopolysaccharide-induced depressive-like behavior and the expression of inflammatory cytokines in the rat prefrontal cortex. Mol. Med. Rep. 2013, 8:887-890.
82. Yu J.J., Zhang Y., Wang Y., Wen Z.Y., Liu X.H., Qin J., Yang J.L. Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway. Psychopharmacology 2013, 225:361-372.
83. Zhao M., Zhou A., Xu L., Zhang X. The role of TLR4-mediated PTEN/PI3K/AKT/NF-kappaB signaling pathway in neuroinflammation in hippocampal neurons. Neuroscience 2014, in press.
84. Zhong L.M., Zong Y., Sun L., Guo J.Z., Zhang W., He Y., Song R., Wang W.M., Xiao C.J., Lu D. Resveratrol inhibits inflammatory responses via the mammalian target of rapamycin signaling pathway in cultured LPS-stimulated microglial cells. PLoS ONE 2012, 7:e32195.